Development of a tolerogenic immune balance and elimination of autoreactive B cells--two important effects of antithymocyte globulin treatment.
Söderström
T
T
Department of Clinical Immunology, Sahlgrenska Sjukhuset, Göteborg, Sweden.
Olausson
M
M
Blohmé
I
I
Enskog
A
A
Mjörnstedt
L
L
Wramner
L
L
Kjellson
B
B
Brynger
H
H
D015703:Antigens, CD / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D015704:CD4 Antigens / Q000032:analysis / Q000276:immunology; D016827:CD8 Antigens; D006084:Graft Rejection; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008212:Lymphocyte Depletion; D008297:Male; D016035:Pancreas Transplantation / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D000961:Antilymphocyte Serum; D015704:CD4 Antigens; D016827:CD8 Antigens; D006684:HLA-DR Antigens